Aclaris Announces Pricing of Public Offering of Common Stock
January 20 2021 - 8:45AM
Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced the
pricing of its underwritten public offering of 5,483,714 shares of
its common stock at a price to the public of $17.50 per share.
In addition, Aclaris has granted to the underwriters a 30-day
option to purchase up to 822,557 additional shares of common stock
at the public offering price, less the underwriting discount. The
gross proceeds from the offering to Aclaris are expected to be
approximately $96.0 million, before deducting underwriting
discounts and commissions and offering expenses, but excluding any
exercise of the underwriters’ option. The offering is expected to
close on or about January 22, 2021, subject to customary closing
conditions.
Cantor Fitzgerald & Co. and William Blair & Company,
L.L.C. are acting as joint book-running managers for the offering.
H.C. Wainwright & Co., LLC is acting as lead manager for the
offering.
A shelf registration statement relating to this offering was
filed with the Securities and Exchange Commission (SEC) on March
13, 2020 and declared effective by the SEC on April 29, 2020.
The offering is being made only by means of a written prospectus
and prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering has been filed
with the SEC and is available on the SEC’s website at
www.sec.gov. A final prospectus supplement and accompanying
prospectus will be filed with the SEC. When available, copies
of the final prospectus supplement and the accompanying prospectus
may also be obtained by contacting Cantor Fitzgerald & Co.,
Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY
10022; Email: prospectus@cantor.com; or William Blair &
Company, L.L.C., Attention: Prospectus Department, 150 North
Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687
or by email at prospectus@williamblair.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Aclaris Therapeutics, Inc., including
statements about Aclaris’ public offering related to expected gross
proceeds and anticipated closing date, and other statements
containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important
factors, including: the uncertainties related to market conditions
and the completion of the public offering on the anticipated terms
or at all and such other factors as are set forth in the risk
factors detailed in Aclaris’ Annual Report on Form 10-K for the
year ended December 31, 2019, Aclaris’ Quarterly Report on Form
10-Q for the quarter ended September 30, 2020, and other filings
Aclaris makes with the SEC from time to time. In addition,
the forward-looking statements included in this press release
represent Aclaris’ views as of the date hereof. Aclaris anticipates
that subsequent events and developments will cause Aclaris’ views
to change. However, while Aclaris may elect to update these
forward-looking statements at some point in the future, Aclaris
specifically disclaims any obligation to do so. These
forward-looking statements should not be relied upon as
representing Aclaris’ views as of any date subsequent to the date
hereof.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Sep 2023 to Sep 2024